The DOI matches its Crossref record.
Escort aptamers: a delivery service for diagnosis and therapy
Open accessAbstract
In 1990, the discovery of aptamers by Tuerk and Gold (1) and subsequently by Ellington and Szostak (2) spawned significant interest within academia and industry.Aptamers have quickly become valuable research tools (3-5).More than that, a therapeutic aptamer (6) has entered clinical evaluation just eight years after the inception of the technology.While aptamers have built inroads into therapeutic applications, they may also become important in vitro diagnostic tools (7).Here, we discuss a new development: the use of "escort aptamers" as targeting agents for in vivo diagnosis and therapy.Instead of directly interrupting a disease process, as would a function-blocking aptamer, escort aptamers are designed to deliver radionuclides, toxins, or cytotoxic agents to diseased tissue.Specifically, we focus on the delivery of benign radionuclides for in vivo diagnosis of disease.For discussion of function-blocking aptamers, see White et al., this Perspective series (8). Aptamers and antibodiesThe advent of monoclonal antibodies in 1974 brought to mind Paul Ehrlich's turn-of-the-century insight that molecules could serve as "magic bullets" that home to pathological organisms with precision (http://nobel.sdsc.edu/medicine/laureates/1908/ehrlich-bio.html).Indeed, the high affinity and specificity of antibodies provide some of the key properties in Ehrlich's concept.Despite some successes in tissue targeting, antibodies are saddled with a fundamental disadvantage: their large size (∼155 kDa) results in slow tissue penetration and long blood residence.For example, in clinical settings where an antibody is coupled to a cellkilling radionuclide, this long circulation half-life leads to bone marrow toxicity that limits the permissible dose (9).To decrease blood half-life while maintaining target specificity, a second generation of smaller antibody fragments has been designed (10,11).Antibody pretargeting strategies also show promise (12-14), and small peptides can have excellent pharmacokinetic profiles (15).However, many approaches are limited by complexity of clinical protocols, paucity of available targeting molecules, low-
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
SELEX—A (r)evolutionary method to generate high-affinity nucleic acid ligands
Stoltenburg, R., Reinemann, C., & Strehlitz, B. (2007) · Biomolecular Engineering · doi:10.1016/j.bioeng.2007.06.001 · Cited by 1,430
Aptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Functional Aptamers and Aptazymes in Biotechnology, Diagnostics, and Therapy
Famulok, M., Hartig, J. S., & Mayer, G. (2007) · Chemical Reviews · doi:10.1021/cr0306743 · Cited by 887
Daniels, D. A., Chen, H., Hicke, B. J., Swiderek, K. M., & Gold, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2136683100 · Cited by 567
Self-citationRNA aptamers as reversible antagonists of coagulation factor IXa
Rusconi, C. P., Scardino, E., Layzer, J., Pitoc, G. A., Ortel, T. L., Monroe, D., & Sullenger, B. A. (2002) · Nature · doi:10.1038/nature00963 · Cited by 512
Aptamer mediated siRNA delivery
Chu, T. C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl388 · Cited by 446
Polymeric nanoparticles for cancer therapy
Parveen, S., & Sahoo, S. K. (2008) · Journal of Drug Targeting · doi:10.1080/10611860701794353 · Cited by 427
Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Ni, X., Castanares, M., Mukherjee, A., & Lupold, S. E. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797189600 · Cited by 349
siRNA Conjugate Delivery Systems
Jeong, J. H., Mok, H., Oh, Y.-K., & Park, T. G. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800278e · Cited by 338
Tenascin-C Aptamers Are Generated Using Tumor Cells and Purified Protein
Hicke, B. J., Marion, C., Chang, Y.-F., Gould, T., Lynott, C. K., Parma, D., Schmidt, P. G., & Warren, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104651200 · Cited by 324
Self-citationEmerging clinical applications of RNA
Sullenger, B. A., & Gilboa, E. (2002) · Nature · doi:10.1038/418252a · Cited by 318
Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 Therapy
Zhou, J., Li, H., Li, S., Zaia, J., & Rossi, J. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.92 · Cited by 301
Application of locked nucleic acids to improve aptamer in vivo stability and targeting function
Schmidt, K. S. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh862 · Cited by 287
Aptamer:Toxin Conjugates that Specifically Target Prostate Tumor Cells
Chu, T. C., Marks, J. W., Lavery, L. A., Faulkner, S., Rosenblum, M. G., Ellington, A. D., & Levy, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4583 · Cited by 284
Zhou, J., Swiderski, P., Li, H., Zhang, J., Neff, C. P., Akkina, R., & Rossi, J. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp185 · Cited by 267
Nanoparticle–aptamer bioconjugates for cancer targeting
Farokhzad, O. C., Karp, J. M., & Langer, R. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.3.311 · Cited by 256
Polymeric micelles for siRNA delivery
Falamarzian, A., Xiong, X.-B., Uludag, H., & Lavasanifar, A. (2012) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(12)50004-3 · Cited by 25
Metadata
- Authors
- Hicke, B. J., & Stephens, A. W.
- Venue
- Journal of Clinical Investigation
- Published
- 2000-10-15
- Volume
- 106
- Issue
- 8
- Pages
- 923-928
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2071745634
- Cited by
- 169
- References
- 0
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.